Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers (Q24611865)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers	scientific article

Statements

scholarly article

0 references

Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

Robert Cook-Deegan

1

0 references

author name string

Christopher DeRienzo

2

0 references

Julia Carbone

3

0 references

Subhashini Chandrasekharan

4

0 references

Christopher Heaney

5

0 references

Christopher Conover

6

0 references

language of work or name

0 references

publication date

April 2010

0 references

Genetics in Medicine

0 references

12

0 references

4 Suppl

0 references

S15-38

0 references

EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

7 April 2017

Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

7 April 2017

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

7 April 2017

Myriad Genetics: In the eye of the policy storm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

7 April 2017

Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

Genetic testing for colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: a naturally-occurring experiment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

Managed care in the genomics era: assessing the cost effectiveness of genetic tests.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

Effects of patents and licenses on the provision of clinical genetic testing services

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

AGA technical review on hereditary colorectal cancer and genetic testing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

A highly accurate, low cost test for BRCA1 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

27 September 2017

Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

30 May 2018

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

30 May 2018

Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Factors influencing health insurers' decisions to cover new genetic technologies

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Testing for BRCA1 mutations: a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer).

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations.

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

The benefits and costs of tamoxifen for breast cancer prevention

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Genetic testing, ethical concerns, and the role of patent law

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis

1 reference

https://api.crossref.org/works/10.1097%2FGIM.0B013E3181D5A67B

21 January 2018

Couples cull embryos to halt heritage of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

28 November 2018

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

28 November 2018

Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: reactions from women and their physicians in a managed care organization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

28 November 2018

Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

28 November 2018

Colorectal cancer test use among persons aged > or = 50 years--United States, 2001.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

28 November 2018

Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

28 November 2018

Genetic testing, ethical concerns, and the role of patent law

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

28 November 2018

Disease gene patents: overcoming unethical constraints on clinical laboratory medicine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047448

28 November 2018

Comprehensive cost-utility analysis of newborn screening strategies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20393305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20393305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Architectures of genetic medicine: comparing genetic testing for breast cancer in the USA and the UK

1 reference

https://pubmed.ncbi.nlm.nih.gov/20393305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20393305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution

1 reference

https://pubmed.ncbi.nlm.nih.gov/20393305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population

1 reference

https://pubmed.ncbi.nlm.nih.gov/20393305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Writing Effective Insurance Justification Letters for Cancer Genetic Testing: A Streamlined Approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/20393305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NCCN clinical practice guidelines in oncology. Colorectal cancer screening

1 reference

https://pubmed.ncbi.nlm.nih.gov/20393305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of financial factors in acceptance of clinical BRCA genetic testing

1 reference

https://pubmed.ncbi.nlm.nih.gov/20393305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/GIM.0B013E3181D5A67B

0 references

Dimensions Publication ID

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24611865&oldid=2175208655"